Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Jul;78(1):6-13.
doi: 10.1038/bjc.1998.434.

A Phase I Study of the Vitamin D Analogue EB 1089 in Patients With Advanced Breast and Colorectal Cancer

Free PMC article
Clinical Trial

A Phase I Study of the Vitamin D Analogue EB 1089 in Patients With Advanced Breast and Colorectal Cancer

T Gulliford et al. Br J Cancer. .
Free PMC article


Preclinical studies have shown that the vitamin D analogue EB 1089 has significantly less calcaemic activity than its parent compound 1,25-dihydroxyvitamin D (1,25(OH)2D3) and significant anti-tumour activity. This phase I trial was designed to evaluate the calcaemic effect of the drug in patients with advanced cancer. EB 1089 was given to 36 patients with advanced breast and colorectal cancer in doses of between 0.15 and 17.0 microg m(-2) day(-1). Serial serum and urine calcium, urine creatinine and serum parathyroid hormone (PTH) were monitored. Hypercalcaemia was seen in all patients receiving 17.0 microg m(-2) day(-1). Hypercalcaemia attributable to EB 1089 was reversible by discontinuing or reducing EB 1089 therapy. During the first 5 days of treatment, urine calcium (P = 0.0001) and serum-corrected calcium (P = 0.027) were related to EB 1089 dose, whereas serum parathyroid hormone (P = 0.0001) showed an inverse relationship. Twenty-one patients received compassionate treatment for between 10 and 234 days. No complete or partial responses were seen. Six patients on treatment for more than 90 days showed stabilization of disease. EB 1089 was well tolerated and adverse events considered to be caused by EB 1089 were limited to dose-dependent effects on calcium metabolism. The dose estimated to be tolerable for most patients from this study is around 7 microg m(-2) day(1). These data support previous work that has demonstrated EB 1089 to be significantly less calcaemic than 1,25-dihydroxyvitamin D3.

Cited by 35 articles

See all "Cited by" articles


    1. Endocrinology. 1983 Dec;113(6):1950-7 - PubMed
    1. Proc Natl Acad Sci U S A. 1983 Oct;80(19):5907-11 - PubMed
    1. Int J Cancer. 1987 Jan 15;39(1):1-5 - PubMed
    1. Cancer Res. 1987 Dec 15;47(24 Pt 1):6793-9 - PubMed
    1. Biochem Pharmacol. 1988 Mar 1;37(5):889-95 - PubMed

Publication types